Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate-Reference-Cited by-同舟云学术

Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate

Published:2009-04-26 Issue:5 Volume:41 Page:619-624
ISSN:1061-4036
Container-title:Nature Genetics
language:en
Short-container-title:Nat Genet

Author:

Carver Brett S,Tran Jennifer,Gopalan Anuradha,Chen Zhenbang,Shaikh Safa,Carracedo Arkaitz,Alimonti Andrea,Nardella Caterina,Varmeh Shohreh,Scardino Peter T,Cordon-Cardo Carlos,Gerald William,Pandolfi Pier Paolo

Publisher

Springer Science and Business Media LLC

Subject

Genetics

Link

http://www.nature.com/articles/ng.370.pdf

Reference26 articles.

1. Tomlins, S.A. et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310, 644–648 (2005).

2. Tu, J.J. et al. Gene fusions between TMPRSS2 and ETS family genes in prostate cancer: frequency and transcript variant analysis by RT-PCR and FISH on paraffin-embedded tissues. Mod. Pathol. 20, 921–928 (2007).

3. Perner, S. et al. TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion. Am. J. Surg. Pathol. 31, 882–888 (2007).

4. Hermans, K.G. et al. Two unique novel prostate-specific and androgen-regulated fusion partners of ETV4 in prostate cancer. Cancer Res. 68, 3094–3098 (2008).

5. Helgeson, B.E. et al. Characterization of TMPRSS2:ETV4 and SLC45A3:ETV5 gene fusions in prostate cancer. Cancer Res. 68, 73–80 (2008).

Cited by 552 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nanomedicines in diagnosis and treatment of prostate cancers: an updated review;Frontiers in Bioengineering and Biotechnology;2024-08-21

2. Diverse landscape of genetically engineered mouse models: Genomic and molecular insights into prostate cancer;Cancer Letters;2024-07

3. JUN mediates the senescence associated secretory phenotype and immune cell recruitment to prevent prostate cancer progression;Molecular Cancer;2024-05-29

4. Disrupting prostate cancer research: Challenge accepted; report from the 2023 Coffey‐Holden Prostate Cancer Academy Meeting;The Prostate;2024-04-29

5. Identification of genes that promote PI3K pathway activation and prostate tumour formation;Oncogene;2024-04-23